Literature DB >> 23205278

Anti-angiogenic agents in Non-Small-Cell Lung Cancer (NSCLC): a perspective on the MONET1 (Motesanib NSCLC Efficacy and Tolerability) study.

Millie Das1, Heather Wakelee.   

Abstract

Entities:  

Year:  2012        PMID： 23205278      PMCID： PMC3506785          DOI： 10.3978/j.issn.2072-1439.2012.10.02

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  22 in total

Review 1.  Tumor angiogenesis: therapeutic implications.

Authors:  J Folkman
Journal:  N Engl J Med       Date:  1971-11-18       Impact factor: 91.245

2.  Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

Authors:  Giorgio Scagliotti; Silvia Novello; Joachim von Pawel; Martin Reck; José Rodrigues Pereira; Michael Thomas; José Elias Abrão Miziara; Beatrix Balint; Filippo De Marinis; Alan Keller; Osvaldo Arén; Maria Csollak; Istvan Albert; Carlos Henrique Barrios; Francesco Grossi; Maciej Krzakowski; Lisa Cupit; Frank Cihon; Sandra Dimatteo; Nasser Hanna
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

3.  Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.

Authors:  Petros G Nikolinakos; Nasser Altorki; David Yankelevitz; Hai T Tran; Shaoyu Yan; Dilip Rajagopalan; Walter Bordogna; Lone H Ottesen; John V Heymach
Journal:  Cancer Res       Date:  2010-03-09       Impact factor: 12.701

4.  VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials.

Authors:  Diether Lambrechts; Bart Claes; Paul Delmar; Joke Reumers; Massimiliano Mazzone; Betül T Yesilyurt; Roland Devlieger; Chris Verslype; Sabine Tejpar; Hans Wildiers; Sanne de Haas; Peter Carmeliet; Stefan J Scherer; Eric Van Cutsem
Journal:  Lancet Oncol       Date:  2012-05-17       Impact factor: 41.316

5.  Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer.

Authors:  Michael B Bass; Steven I Sherman; Martin J Schlumberger; Martn J Schlumberger; Michael T Davis; Lisa Kivman; Huan-Mei Khoo; Kimberly H Notari; Matthew Peach; Yong-Jiang Hei; Scott D Patterson
Journal:  J Clin Endocrinol Metab       Date:  2010-08-25       Impact factor: 5.958

6.  International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.

Authors:  Giorgio V Scagliotti; Ihor Vynnychenko; Keunchil Park; Yukito Ichinose; Kaoru Kubota; Fiona Blackhall; Robert Pirker; Rinat Galiulin; Tudor-Eliade Ciuleanu; Oleksandr Sydorenko; Mircea Dediu; Zsolt Papai-Szekely; Natividad Martinez Banaclocha; Sheryl McCoy; Bin Yao; Yong-Jiang Hei; Francesco Galimi; David R Spigel
Journal:  J Clin Oncol       Date:  2012-07-02       Impact factor: 44.544

Review 7.  Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders.

Authors:  M Autiero; A Luttun; M Tjwa; P Carmeliet
Journal:  J Thromb Haemost       Date:  2003-07       Impact factor: 5.824

8.  Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study.

Authors:  Afshin Dowlati; Robert Gray; Alan B Sandler; Joan H Schiller; David H Johnson
Journal:  Clin Cancer Res       Date:  2008-03-01       Impact factor: 12.531

9.  Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer.

Authors:  Luis G Paz-Ares; Bonne Biesma; David Heigener; Joachim von Pawel; Timothy Eisen; Jaafar Bennouna; Li Zhang; Meilin Liao; Yan Sun; Steven Gans; Kostas Syrigos; Etienne Le Marie; Maya Gottfried; Johan Vansteenkiste; Vincente Alberola; Uwe Phillip Strauss; Elaine Montegriffo; Teng Jin Ong; Armando Santoro
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544

10.  Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.

Authors:  Richard H de Boer; Óscar Arrieta; Chih-Hsin Yang; Maya Gottfried; Valorie Chan; Johann Raats; Filippo de Marinis; Raymond P Abratt; Jürgen Wolf; Fiona H Blackhall; Peter Langmuir; Tsveta Milenkova; Jessica Read; Johan F Vansteenkiste
Journal:  J Clin Oncol       Date:  2011-01-31       Impact factor: 44.544
View more
  3 in total

1.  Efficacy and safety of albumin-bound paclitaxel in treating recurrent advanced non-small-cell lung cancer.

Authors:  Pu-Yuan Xing; Jun-Ling Li; Yan Wang; Xue-Zhi Hao; Bin Wang; Lin Yang; Yuan-Kai Shi; Xiang-Ru Zhang
Journal:  Chin J Cancer Res       Date:  2013-04       Impact factor: 5.087

Review 2.  Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitors.

Authors:  Mridul Roy; Yu-Hao Luo; Mao Ye; Jing Liu
Journal:  Biomed Res Int       Date:  2013-07-01       Impact factor: 3.411

3.  Successful chemotherapy with nab-Paclitaxel in a heavily treated non-small cell lung cancer patient: a case report.

Authors:  Mikiko Ishihara; Satoshi Igawa; Sachiyo Maki; Shinya Harada; Seiichiro Kusuhara; Hideyuki Niwa; Sakiko Otani; Jiichiro Sasaki; Shi-Xu Jiang; Noriyuki Masuda
Journal:  Case Rep Oncol       Date:  2014-06-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.